Repligen Corp. (NASDAQ:RGEN) has been assigned a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. Repligen Corp.’s rating score has declined by 11.3% from 90 days ago as a result of various analysts’ ratings changes.
Brokers have set a 12 month consensus target price of $33.67 for the company and are forecasting that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also given Repligen Corp. an industry rank of 109 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut shares of Repligen Corp. from a “hold” rating to a “sell” rating in a research report on Saturday, July 30th.
In other Repligen Corp. news, Director Thomas F. Ryan, Jr. sold 2,700 shares of Repligen Corp. stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $32.58, for a total transaction of $87,966.00. Following the transaction, the director now owns 9,394 shares of the company’s stock, valued at approximately $306,056.52. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 2.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors boosted its position in Repligen Corp. by 3.8% in the second quarter. BlackRock Fund Advisors now owns 2,551,928 shares of the company’s stock valued at $69,821,000 after buying an additional 94,572 shares in the last quarter. Vanguard Group Inc. boosted its position in Repligen Corp. by 7.0% in the second quarter. Vanguard Group Inc. now owns 1,565,708 shares of the company’s stock valued at $42,838,000 after buying an additional 102,030 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in Repligen Corp. by 3.5% in the third quarter. Conestoga Capital Advisors LLC now owns 1,094,805 shares of the company’s stock valued at $33,052,000 after buying an additional 37,217 shares in the last quarter. Renaissance Technologies LLC boosted its position in Repligen Corp. by 25.6% in the first quarter. Renaissance Technologies LLC now owns 982,404 shares of the company’s stock valued at $26,348,000 after buying an additional 200,300 shares in the last quarter. Finally, State Street Corp boosted its position in Repligen Corp. by 4.3% in the second quarter. State Street Corp now owns 943,738 shares of the company’s stock valued at $25,823,000 after buying an additional 38,549 shares in the last quarter. 89.37% of the stock is currently owned by hedge funds and other institutional investors.
Repligen Corp. (NASDAQ:RGEN) remained flat at $29.32 during trading on Monday. 64,049 shares of the company traded hands. The company has a 50-day moving average of $31.51 and a 200 day moving average of $28.01. The company has a market capitalization of $990.61 million, a price-to-earnings ratio of 117.28 and a beta of 1.36. Repligen Corp. has a 52-week low of $20.07 and a 52-week high of $36.00.
Repligen Corp. (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.03. Repligen Corp. had a net margin of 8.69% and a return on equity of 10.74%. The business had revenue of $29.20 million for the quarter, compared to analysts’ expectations of $24.75 million. During the same quarter last year, the firm earned $0.11 EPS. The firm’s revenue for the quarter was up 35.8% compared to the same quarter last year. On average, equities research analysts predict that Repligen Corp. will post $0.44 earnings per share for the current fiscal year.
About Repligen Corp.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.